Condition: Hepato Cellular Carcinoma (HCC) · Sponsor: Epiliquid Holding, Inc
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
This description comes directly from the study's public registry record.
Dr. Victoria Bocanegra, MD, PhD. · +5492616603254 · victoria.bocanegra@epiliquid.com
Dr. Emanuel Campoy, PhD. · +5492615997899 · emanuel.campoy@epiliquid.com
Always discuss trial participation with your own doctor first.
| Epiliquid | Mendoza, Argentina | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07148310